277 Treatment of aphthous ulcers with montelukast

Aphthous ulcers are the most prevalent oral mucosal lesions, yet treatment is challenging. There evidence that montelukast efficacious in treating aphthous ulcers. A randomized placebo-controlled trial comparing against prednisone for recurrent stomatitis demonstrated has superior efficacy compared with placebo, decreased prednisone, but adverse effects to prednisone. Our single-center, retrospective study identified subjects a minimum of 2 distinct encounters using search term:(Singular or montelukast) AND (aphthous ulcers). 16 met inclusion criteria and were found have follow up after treatment. Over half (56.3%) patients had positive clinical responses, measured by provider assessment. Among these, 44.4% reduction number ulcers, 22.2% decrease frequency ulcer eruptions, remainder unspecified improvement. Mean dosing was 9 mg daily, range 4-10 mg. 4-5 prescribed pediatric patients;10 all others aged 15 older. While 10% aforementioned RCT reported side effect diarrhea from montelukast, none our any effects, despite mean therapy duration 455.4 days (measured encounter dates). We unable determine an accurate time response due longer durations between without specific documentation response. The active months. demonstrates lasting as at last related encounter. further strengthens support safe effective option recalcitrant both Montelukast minimal even long duration, other systemic medications used management. Further studies recurrence rate cessation warranted.